ARDX

2.9902.29%
DM

David M. Mott

Independent Chairman of the Board

Mr. David M. Mott, also known as Dave, has been an Independent Director of Novavax, Inc. since June 14, 2020 and serves as its Chairman of the Board of Director from 2026. He serves as the Board Chair of Vtesse, Inc. Mr. Mott has been a private Investor through Mott Family Capital since February 2020. He served as an Independent Chairman of Imara, Inc. unti 2023 and had been its Independent Director since January 2016 until 2023. He had been Chairman of Epizyme, Inc. since April 2016 until August 12, 2022. He has been the Chairman of Ardelyx, Inc. since March 2014. He serves as the Chairman of Supervisory Board at BioMarin Nederland B.V. He served as an Executive Chairman of Sagimet Biosciences, Inc. until 2020. He served as a General Partner at New Enterprise Associates, Inc. from September 2008 to February 2020. He previously served as a Partner and Head of Healthcare Investing at New Enterprise Associates; Inc. Mr. Mott joined the firm on September 17, 2008. Mr. Mott focused on healthcare and biopharmaceuticals investments. He is Advisory Board Member at Bowside Capital LLC. He serves as a Senior Advisor of The Royal Institute of International Affairs. He serves as a Senior Advisor of Chatham House. He had been the Chairman of Mersana Therapeutics, Inc. since July 2012 until January 05, 2026. He served as the Executive Chairman of Prosensa Holding NV. He served as an Executive Vice President of AstraZeneca PLC since June 2007 until July 2008. He joined MedImmune Inc. in April 1992 as a Vice President with responsibility for business development, strategic planning and Investor Relations and assumed additional responsibility for the medical and regulatory groups, in 1994. He served as the Chief Executive Officer of MedImmune Inc. from October 2000 to July 31, 2008 and served as its President from February 2004 to July 31, 2008. Mr. Mott served as the Chief Financial Officer and Executive Vice President of MedImmune Inc. since March 1995 and served as its President and Chief Operating Officer since November 1995. From 1992 to 2008, he worked at MedImmune Limited which including Chief Operating Officer and Chief Financial Officer. He also served as the Chief Executive Officer and President of MedImmune Limited from June 18, 2007 to July 2008. He previously served on the Board of Tiburio Therapeutics, Inc., a biopharmaceutical company, from December 2018 to February 2020, Nightstar Therapeutics plc, a public gene therapy company that was acquired by Biogen in June 2019, from November 2015 to June 2019. In 2002, he founded MedImmune Ventures, Inc. and departed in July 2008. Prior to joining MedImmune Inc., he served as a Vice President in the Health Care Investment Banking Group at Smith Barney, Harris Upham & Co. Inc. At Smith Barney, where he was employed from July 1986 to April 1992, his activities included public and private equity and debt financings as well as merger and acquisition work for biotechnology, healthcare services and medical product and device companies. He served as Vice President of Health Care Investment Banking Group at Citigroup CIB. He served as the Chairman of Tesaro, Inc. since July 2011 until January 2019. He served as the Chairman of Cydan II, Inc. He served as the Chairman of Conceptis Technologies, Inc. He had been the Independent Chairman of Adaptimmune Therapeutics plc since January 1, 2017 until November 14, 2025 and served as its Vice Chairman from May 2016 to December 1, 2016. He is a Director of Polyneuron. He served as the Chairman of Zyngenia, Inc. from 2009 to 2014. Mr. Mott served as Vice Chairman of MedImmune, LLC from October 1998 to June 1, 2007. He has been Member of Supervisory Board at BioMarin Nederland B.V. since January 25, 2012 and serves as its Member of the Board of Directors. He has been a Director of Edimer Pharmaceuticals Inc. since June 30, 2013. He has been a Non-Executive Director at Complexa, Inc. since July 26, 2017 and is its Chairman of the Board since 2018. He serves as a Director of St Albans School and Biotechnology Innovation Organization (a/k/a: Biotechnology Industry Organization (BIO). He had been Non-Executive Director of Adaptimmune Therapeutics plc since February 2015 until November 14, 2025. He served as Non-Executive Director at Nightstar Therapeutics plc since August 2015 until June 07, 2019. He has been an Independent Director of Ardelyx, Inc. since March 2009. He has been an Independent Director of Epizyme, Inc. since December 2009. He serves as a Member of Advisory Board at Scripps Research Translational Institute (formerly, Scripps Translational Science Institute (stsi), Board of Trustees of St. Jamfes School and on the Board of Governors of Beauvoir, the National Cathedral Elementary School. He serves as a Member of the Board of Directors of NightstaRx Limited. He served as a Director of Tesaro, Inc since May 2010 until January 22, 2019. He has been a Director of XTuit Pharmaceuticals, Inc. since June 11, 2015. He served on numerous public and private company boards in the biopharmaceutical industry. He served as a Director of Omthera Pharmaceuticals, Inc. from April 2011 to July 18, 2013. He served as a Director of Zosano Pharma Corporation, MdBio, Inc. and of Maryland Tech Council. He served as a Director at Clementia Pharmaceuticals Inc. since June 2015 until February 27, 2018. He served as a Director of Melinta Therapeutics, Inc. until September 2008 and served as its Independent Director. He also serves on the Board of Directors of several privately held life sciences companies. He served as a Director of Ambit Pharmaceuticals and Rib-X Pharmaceuticals. He served as a Director of Ambit Biosciences Corporation since November 2007. He served as a Director of MedImmune, LLC from November 1995 to June 1, 2007. He served as a Non-Executive Director of Shire plc from October 31, 2007 to October 30, 2009. Mr. Mott holds BA degree in Economics and Government from Dartmouth College.

Positions